Johnson & Johnson JNJ

$253.79 -1.77 (-0.69%)

Valuation

Market cap
615,873,536,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.78
Forward PE
22.78
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,847,935
Avg volume
6,859,124
Day's range
$251.50 – $255.56
Shares out
2,409,898,000
Stochastic %K
45%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

HKLM93 Oct 20, 11:16 AM
$SLS cmon $JNJ break the news
0 replies
jbess22 Oct 20, 11:13 AM 0 replies
chursinow62 Oct 20, 10:00 AM 0 replies
husnain96 Oct 20, 9:12 AM
$JNJ $ACHR Spectrum rights are only the starting line. SpaceX would still need operational execution, device support and customer trust to build a serious mobile business.
1 replies
TopOptionAlert Oct 20, 6:47 AM
$JNJ NOV20 265C · still actionable Zone: $252.01 to $255.57 Invalidation: close under $245.17 Objectives: $265.35, then $281.07 The math: up 4.6% to the first objective and 10.7% to the second, against 3.4% risk on the invalidation, better than 3 to 1 to the second Dear friend, picture a big steady company that just took a hard knock and then stood back up. Johnson and Johnson beat its October 13 earnings estimate and the stock fell to $245.17 that day, then buyers stepped in and held the price above that low through a choppy week. That is a swing setup to me, a washed out name holding a real level with room to walk back toward $265.35 first. What that means is simple, we risk a close under the earnings day low to see if the bounce can grow legs. P.S. Watch $251.50, the low from the latest session, because holding above it keeps the bounce picture clean.
0 replies
jbess22 Oct 19, 10:41 PM 0 replies
HKLM93 Oct 19, 6:02 PM
$SLS 🤝 $JNJ
1 replies
SellasgpsCurativeBAT11 Oct 19, 5:08 PM
$ABBV $AZN $JNJ $PFE $SLS Dr. Stergiou At the May 19 Stifel presentation, CEO Angelos Stergiou said GPS was being administered to patients "even three years out at this point." At the May 27 Cowen oncology summit, he explained that treatment had been extended beyond the original one-year schedule, eventually beyond three years, at the request of physicians who assessed that their patients were benefiting. As a Biostatistician compelling reason to pay attention. Continued treatment years later, with physicians requesting the option to keep dosing, fits the possibility of durable benefit. ✌️🙏❤️‍🩹
1 replies